Findings also show improved persistence with high-potency, obesity-approved GLP-1 products

Real-world study of GLP-1 patients continues to deliver leading insights

Real-world, integrated data follows-up on previous insights, analytics.

Prime to present seven studies and receive the 2024 JMCP Award for Excellence

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting.

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care